• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Novavax Inc.

    4/8/26 6:00:09 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NVAX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 6)


    NOVAVAX, INC.

    (Name of Issuer)


    Common Stock, Par Value $0.01 per share

    (Title of Class of Securities)




    670002401

    (CUSIP Number)
    Himanshu H. Shah
    2301 Sugar Bush Road, Suite 510
    Raleigh, NC, 27612
    (919) 719-6360

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    04/08/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    schemaVersion:


    SCHEDULE 13D

    CUSIP Number(s):
    670002401


    1 Name of reporting person

    Shah Capital Management
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NORTH CAROLINA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    14,719,738.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    14,719,738.00
    11Aggregate amount beneficially owned by each reporting person

    14,719,738.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    9.03 %
    14Type of Reporting Person (See Instructions)

    IA



    SCHEDULE 13D

    CUSIP Number(s):
    670002401


    1 Name of reporting person

    Shah Capital Opportunity Fund LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    14,000,000.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    14,000,000.00
    11Aggregate amount beneficially owned by each reporting person

    14,000,000.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.59 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP Number(s):
    670002401


    1 Name of reporting person

    Himanshu H. Shah
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    125,359.00
    8Shared Voting Power

    14,719,738.00
    9Sole Dispositive Power

    125,359.00
    10Shared Dispositive Power

    14,719,738.00
    11Aggregate amount beneficially owned by each reporting person

    14,845,097.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    9.11 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, Par Value $0.01 per share
    (b)Name of Issuer:

    NOVAVAX, INC.
    (c)Address of Issuer's Principal Executive Offices:

    700 QUINCE ORCHARD ROAD, GAITHERSBURG, MARYLAND , 20878.
    Item 1 Comment:
    The following constitutes Amendment No. 6 to the Schedule 13D filed by the undersigned (the "Amendment No. 6"). This Amendment No. 6 amends the Schedule 13D as specifically set forth herein.
    Item 2.Identity and Background
    (a)
    (i) Shah Capital Management, Inc. ("Shah Capital"), a North Carolina corporation, who serves as the investment adviser to Shah Opportunity (as defined below); (ii) Shah Capital Opportunity Fund LP ("Shah Opportunity"), a Delaware limited partnership; and (iii) Himanshu H. Shah ("Mr. Shah"), who serves as President and Chief Investment Officer of Shah Capital. Shah Capital, Shah Opportunity and Mr. Shah are referred to collectively as the "Reporting Persons."
    (b)
    The address of the principal business and principal office of each of the Reporting Persons is: 2301 Sugar Bush Road, Suite 510 Raleigh, North Carolina 27612
    (c)
    The principal business of each of Shah Capital and Shah Opportunity is investing in securities. The principal occupation of Mr. Shah is serving as the President and Chief Investment Officer of Shah Capital.
    (d)
    During the past five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    During the past five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    Shah Capital is North Carolina corporation. Shah Opportunity is a Delaware limited partnership. Mr. Shah is a citizen of the United States of America.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Item 3 is hereby amended as follows: Except for 125,359 shares owned directly by Mr. Shah, which were purchased using his personal funds, all of the shares to which this Statement relates were purchased on behalf of the Reporting Persons using the investment capital of the Reporting Persons. All shares were purchased in various transactions and for various amounts of consideration through open market purchases.
    Item 4.Purpose of Transaction
     
    Item 4 is hereby amended to add the following: On April 8, 2026, the Reporting Persons sent a letter (the "Shah Capital Open Letter") to the board of directors of the Issuer (the "Board") declaring a notice of intention to vote against Board Nominees and Executive Compensation. The letter outlines a multitude of reasons including, but not limited to: (i) value destruction; (ii) pessimistic 2026 Revenue forecast; (iii) low institutional credibility; (iv) cost discipline and consistent profitability; (v) and necessary governance changes. The foregoing description of the Shah Capital Open Letter does not purport to be complete and is qualified in its entirety to the Shah Capital Open Letter, which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
    Item 5.Interest in Securities of the Issuer
    (a)
    Items 5(a)-(c) are hereby amended and restated to read as follows: The aggregate percentage of the shares of Common Stock reported owned by each person named herein is based upon 162.9M shares outstanding as of February 16, 2026. (i) - Shah Capital Management 14,719,738; 9.03% (ii) - Shah Capital Opportunity Fund LP 14,000,000; 8.59% (iii) - Himanshu H. Shah 14,845,097; 9.11%
    (b)
    (i) - Shah Capital Management Sole Voting Power - 0 Shared Voting Power - 14,719,738 Sole Dispositive Power - 0 Shared Dispositive Power - 14,719,738 (ii) - Shah Capital Opportunity Fund LP Sole Voting Power - 0 Shared Voting Power - 14,000,000 Sole Dispositive Power - 0 Shared Dispositive Power - 14,000,000 (iii) - Himanshu H. Shah Sole Voting Power - 125,359 Shared Voting Power - 14,719,738 Sole Dispositive Power - 125,359 Shared Dispositive Power - 14,719,738 As of the date hereof, Shah Opportunity directly beneficially owns 14,000,000 shares of Common Stock. As the investment manager of Shah Opportunity and the Shah Managed Accounts, Shah Capital Management may be deemed to beneficially own 14,719,738 shares of Common Stock beneficially owned in the aggregate by Shah Opportunity and held in the Shah Managed Accounts. As of the date hereof, Mr. Shah directly beneficially owns 125,359 shares of Common Stock, which are held in the Mr. Shah Managed Account. As the President and Chief Investment Officer of Shah Capital Management, Mr. Shah may be deemed to beneficially own the 14,719,738 shares of Common Stock beneficially owned in the aggregate by Shah Opportunity and held in the Shah Managed Accounts, which in addition to the 125,359 shares of Common Stock he beneficially owns directly, constitutes an aggregate of 14,845,097 shares of Common Stock that Mr. Shah may be deemed to beneficially own.
    (c)
    Transactions in the Shares of the Issuer Since the Filing of Amendment No. 4 to the Schedule 13D: There were no transactions in the past 60 days.
    (d)
    No other person is known to the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of no par value covered by this Statement.
    (e)
    Not Applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    Other than as described in this Statement, to the knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons or between the Reporting Persons and any other persons with respect to any securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit Number Description Exhibit 99.1 Shah Capital Letter dt. April 8, 2026 to NVAX Board of Directors.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Shah Capital Management
     
    Signature:/s/ Himanshu H. Shah
    Name/Title:Himanshu H. Shah, President and Chief Investment Officer
    Date:04/08/2026
     
    Shah Capital Opportunity Fund LP
     
    Signature:/s/ Himanshu H. Shah
    Name/Title:Himanshu H. Shah, Managing Member
    Date:04/08/2026
     
    Himanshu H. Shah
     
    Signature:/s/ Himanshu H. Shah
    Name/Title:Himanshu H. Shah
    Date:04/08/2026
    Get the next $NVAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVAX

    DatePrice TargetRatingAnalyst
    10/24/2025$18.00Overweight
    Cantor Fitzgerald
    8/28/2025$10.00Buy
    H.C. Wainwright
    8/20/2025$7.00Neutral → Underperform
    BofA Securities
    6/17/2025$6.00Sell
    Citigroup
    2/28/2025$19.00Buy
    BTIG Research
    7/30/2024$8.00Neutral → Underweight
    JP Morgan
    5/10/2024$4.00 → $12.00Underperform → Neutral
    BofA Securities
    5/10/2024Underweight → Neutral
    JP Morgan
    More analyst ratings

    $NVAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development

    Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical OfficerDr. Walker will continue advancing Novavax's R&D efforts with a focus on data generation to facilitate partnering discussions, Matrix adjuvant innovation and advancement of the Company pipeline  GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D). Dr. Walker now reports to John C. Jacobs, President and Chief Executive Officer of Novavax.A specialist in internal medicine and pulmonary and critical care medi

    3/30/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax to Participate in Upcoming Investor Conferences

    GAITHERSBURG, Md., Feb. 26, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), today announced that it will participate in the following upcoming investor conferences:TD Cowen 46th Annual Health Care Conference:Fireside ChatDate:Tuesday, March 3, 2026Time:2:30 p.m. Eastern Time (ET)Location:Boston, MALeerink Partners 2026 Global Healthcare Conference:Fireside ChatDate:Tuesday, March 10, 2026Time:3:40 p.m. ETLocation:Miami Beach, FLJefferies Biotech on the Beach Summit:Investor MeetingsDate:Wednesday, March 11, 2026Location:Miami Beach, FLA webcast of the fireside chats will be available through the Events and Presentations page of the Company's website at ir.novavax.com. A replay of each webc

    2/26/26 4:30:00 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areasMultiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027Year end 2025 Cash of $751 million Novavax exceeded its full year 2025 R&

    2/26/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

    For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

    10/3/23 2:56:27 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $NVAX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Novavax Inc.

    SCHEDULE 13D/A - NOVAVAX INC (0001000694) (Subject)

    4/8/26 6:00:09 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Novavax Inc.

    SCHEDULE 13G/A - NOVAVAX INC (0001000694) (Subject)

    3/27/26 11:06:41 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NOVAVAX INC (0001000694) (Filer)

    2/26/26 8:02:10 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Shiver John W. converted options into 7,947 shares (SEC Form 4)

    4 - NOVAVAX INC (0001000694) (Issuer)

    3/12/26 5:00:14 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP, CFO and Treasurer Kelly James Patrick converted options into 12,223 shares and covered exercise/tax liability with 5,904 shares, increasing direct ownership by 5% to 130,599 units (SEC Form 4)

    4 - NOVAVAX INC (0001000694) (Issuer)

    3/9/26 6:13:36 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form 4 filed by EVP, CFO and Treasurer Kelly James Patrick

    4/A - NOVAVAX INC (0001000694) (Issuer)

    3/9/26 6:12:20 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald resumed coverage on Novavax with a new price target

    Cantor Fitzgerald resumed coverage of Novavax with a rating of Overweight and set a new price target of $18.00

    10/24/25 8:05:21 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Novavax with a new price target

    H.C. Wainwright resumed coverage of Novavax with a rating of Buy and set a new price target of $10.00

    8/28/25 8:09:49 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax downgraded by BofA Securities with a new price target

    BofA Securities downgraded Novavax from Neutral to Underperform and set a new price target of $7.00

    8/20/25 8:27:13 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVAX
    Leadership Updates

    Live Leadership Updates

    View All

    Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development

    Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical OfficerDr. Walker will continue advancing Novavax's R&D efforts with a focus on data generation to facilitate partnering discussions, Matrix adjuvant innovation and advancement of the Company pipeline  GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D). Dr. Walker now reports to John C. Jacobs, President and Chief Executive Officer of Novavax.A specialist in internal medicine and pulmonary and critical care medi

    3/30/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax Appoints Charles Newton to Board of Directors

    GAITHERSBURG, Md., April 29, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare investment banking to his role on the Novavax Board of Directors. "Charles brings a wealth of expertise across corporate finance and capital markets to Novavax," said John C. Jacobs, President and Chief Executive Officer, Novavax. "The knowledge he brings to our already experienced board will be invaluable as we continue to execute our corp

    4/29/25 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Brian Rosen, Commercial Strategy Senior Executive, Appointed as Director of Capstone Companies, Inc.

    Capstone Companies, Inc. (OTCQB:CAPC) announced today the appointment of Brian Rosen as a non-employee director, effective January 20, 2025. Mr. Rosen has extensive experience in marketing, business development, contract negotiation and government relations as well as experience as a member of two public companies' management. He served as Senior Vice President, Global Market Access, Public Policy & Alliances (2021 - 2023), Senior Vice President, Commercial Strategy (2018 - 2021) and Vice President, Market Access, Policy, & Government Affairs (2015 - 2017) with Novavax, Inc. (NASDAQ:NVAX). Before Novavax, Inc., Mr. Rosen served as Chief Policy, Advocacy & Patient Services Officer (2014 -

    1/23/25 9:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVAX
    Financials

    Live finance-specific insights

    View All

    Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areasMultiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027Year end 2025 Cash of $751 million Novavax exceeded its full year 2025 R&

    2/26/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows:Conference call details:Date:February 26, 2026Time:8:30 a.m. ETURL to register phone:Register HereDial-in number:(888) 880-3330 (U.S.) or(+1) (646) 357-8766 (International)Webcast:ir.novavax.com/eventsParticipants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants can als

    2/19/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights

    Total revenue of $70 million in the third quarter of 2025Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date including $50 million earned on marketing authorization transfersSanofi reported preliminary positive immunogenicity and safety Phase 1/2 data for Nuvaxovid™ in combination with both Fluzone High-Dose and FlublokSanofi received BARDA grant for pandemic influenza vaccine candidate using Novavax's Matrix-M® adjuvantMaryland site consolidation transactions resulted in $60 million cash proceeds and approximately $230 million in expected future cost savingsRaises Full Year 2025 Revenue Framework and Affirms Financial GuidanceCompany to

    11/6/25 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Novavax Inc.

    SC 13G/A - NOVAVAX INC (0001000694) (Subject)

    11/12/24 4:46:17 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Novavax Inc.

    SC 13G/A - NOVAVAX INC (0001000694) (Subject)

    11/4/24 1:19:04 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Novavax Inc.

    SC 13G/A - NOVAVAX INC (0001000694) (Subject)

    7/10/24 6:16:55 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care